-
Media ReleaseFive nonprofit organizations to receive up to $250,000 through Novartis STEP Program™ to support sickle cell patient initiatives
-
Media ReleaseNovartis issues voluntary nationwide recall of Promacta® 12.5 mg for oral suspension due to potential peanut contamination
-
Media ReleaseNew AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1
-
Media ReleaseAveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients
-
Media ReleaseNovartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
-
Media ReleaseAveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
-
Media ReleaseNovartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
-
Media ReleaseNovartis late-breaking data further support initiation of Entresto in hospital and as a first-choice systolic heart failure therapy in stabilized patients
-
Media ReleaseNovartis data show psoriasis patients treated with Cosentyx® reported improvements in quality of life measures as early as Week 4
-
Media ReleaseNovartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
-
Media ReleaseNovartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
-
Media ReleaseNovartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses